News

All

March 14, 2024

Our collaboration with the Weiskopf lab on redirecting macrophages to target persister cells in oncogene-addicted lung cancers is now published in JCI: Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.

January 18, 2024

Hideko presents on her most recent work “APOBEC3A drives tumor evolution through activation of ERVs in non-small cell lung cancer” at the the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024).

October 18, 2023

Aaron presents at the Regulatory Networks in Health and Disease Seminar series in the Department of Pharmacology and Cancer Biology at Duke Med. Thanks to Kris Wood for hosting a wonderful visit with Duke PCB faculty and students!

October 13, 2023

Chendi presents posters on her most recent work at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: “Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer” and “Aurora Kinase A inhibition overcomes adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer”.

September 28, 2023

Aaron was a featured speaker for the “Art of Scientific Speaking” at the 2023 KF-CCR Annual Retreat!

Awards and Recognition

March 8, 2021

Our paper on mechanisms of resistance crizotinib and lorlatinib in ROS1 fusion-positive lung cancer is now available in Clinical Cancer Research. A true translational team effort!

November 17, 2020

Congratulations to Hideko for receiving a Pilot Grant award from the Lung Cancer Research Foundation to study the role of APOBEC3A in evolution of acquired drug resistance!

November 19, 2019

Congratulations to Hideko for being awarded a MGH ECOR Fund for Medical Discovery Postdoctoral Fellowship Award for her work on evolution of resistance of EGFR mutant lung cancer!